Published online Nov 27, 2026. doi: 10.4240/wjgs.124340
Revised: July 15, 2026
Accepted: September 4, 2026
Published online: November 27, 2026
Processing time: 153 Days and 14.6 Hours
Ivor Lewis esophagectomy is the standard surgical approach for middle and distal esophageal cancer. Despite advances in minimally invasive techniques and perioperative care, anastomotic leakage (AL) remains a major cause of posto
To evaluate the feasibility, safety, and preliminary clinical outcomes of a modi
This retrospective single-center study included 31 patients who underwent Ivor Lewis esophagectomy from July 2019 to June 2024. Sixteen patients received prophylactic ModVAC therapy, while fifteen earlier patients served as historical controls. The primary outcome was AL.
Baseline characteristics were comparable between groups. AL occurred in 25% vs 40% of patients (P = 0.37), with all ModVAC leaks managed non-operatively. Hospital stay, morbidity, and mortality were similar. Protocol completion was 81.25% with minimal device-related complications.
Prophylactic ModVAC is a feasible and safe adjunct following Ivor Lewis esophagectomy. Although leak reduction was not statistically significant, the favorable management of leaks suggests potential clinical benefit. Larger prospective randomized studies are warranted.
Core Tip: Anastomotic leakage remains one of the most serious complications after Ivor Lewis esophagectomy. This study presents the first clinical experience with a modified, endoscopy-independent prophylactic vacuum-assisted closure system (ModVAC) that can be placed intraoperatively using standard surgical materials. ModVAC was feasible, safe, and achieved a high protocol completion rate with minimal device-related complications. Although the reduction in anastomotic leakage did not reach statistical significance in this preliminary cohort, all leaks in the ModVAC group were managed non-operatively, supporting further evaluation of this simple, low-cost prophylactic approach in larger prospective studies.